Ruxolitinib Shows Stronger Response in Primary Than Secondary HLH, Meta-Analysis Finds
A systematic review of 542 patients finds ruxolitinib-based regimens achieve an 87.2 percent overall response rate in hemophagocytic lymphohistiocytosis, with ...
A systematic review of 542 patients finds ruxolitinib-based regimens achieve an 87.2 percent overall response rate in hemophagocytic lymphohistiocytosis, with ...
Hemophagocytic lymphohistiocytosis (HLH) is a severe, potentially life-threatening condition characterized by an unchecked immune response, leading to systemic inflammation. Recent ...
Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm Follow' to start subscribing.
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine